Skip to main content

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

Recruiting · Phase 1, Phase 2 · NCT07013747

Conditions: Acne

At a glance

Research payments reported, 2025
$221,742
U.S. investigators named
3
Sites paid
3
Planned or actual enrollment
228

About the trial

Sponsor
Sanofi Pasteur, a Sanofi Company
Tested
Acne mRNA vaccine (biological), Placebo (other)
Dates
Started 2025-07-03; completion 2030-03-13
Results posted
Not yet

The purpose of the VBE00009 study is to evaluate the safety, efficacy and immunogenicity of 2 administrations of the Acne mRNA vaccine candidate at single dose level in participants aged 18 to 45 years with mild acne. This study will consist of a Core Study followed by an optional Long-Term Extension (LTE). Core Study will include a Sentinel Cohort and a Main Cohort, with the Sentinel Cohort assessing the safety in a stepwise manner. If the participants consent to the LTE, they will be followed up for an additional 30 months after the last planned visit in the Core Study, to assess the long term effects of the vaccine.

From ClinicalTrials.gov, last updated 2026-07-09. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sanofi Pasteur Inc. reported $221,742 in research payments for this study in 2025 (22 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Moore Clinical Research $155,117
  • Delricht Llc $51,624
  • Elias Research Associates Llc $15,000

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.